SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-276930
Filing Date
2022-11-03
Accepted
2022-11-03 16:33:58
Documents
14
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d402663d8k.htm   iXBRL 8-K 25937
2 EX-99.1 d402663dex991.htm EX-99.1 64027
6 GRAPHIC g402663g88y50.jpg GRAPHIC 10856
  Complete submission text file 0001193125-22-276930.txt   234067

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20221103.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20221103_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20221103_pre.xml EX-101.PRE 10804
8 EXTRACTED XBRL INSTANCE DOCUMENT d402663d8k_htm.xml XML 3230
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 221358604
SIC: 2834 Pharmaceutical Preparations